# Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Study · id `cardio:ct-nct01076764` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01076764](<https://clinicaltrials.gov/study/NCT01076764>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01076764

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 13220 participants.

## Technical summary

Registry record NCT01076764. Randomized; triple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 13220 participants (enrolled count; ClinicalTrials.gov record NCT01076764, source copy `cardio:ctgov-nct01076764-2016-05-04`, retrieved 2026-10-31)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01076764, source copy `cardio:ctgov-nct01076764-2016-05-04`, retrieved 2026-10-31)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01076764, source copy `cardio:ctgov-nct01076764-2016-05-04`, retrieved 2026-10-31)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01076764, source copy `cardio:ctgov-nct01076764-2016-05-04`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belarus; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czechia; Egypt; Estonia; France; Germany; Greece; Hong Kong SAR China; Hungary; India; Indonesia; Israel; Italy; Jordan; Latvia; Lebanon; Lithuania; Malaysia; Mexico; Montenegro; Netherlands; New Zealand; North Macedonia; Norway; Panama; Peru; Poland; Portugal; Romania; Russia; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Switzerland; Taiwan; Thailand; Tunisia; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT01076764, source copy `cardio:ctgov-nct01076764-2016-05-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01076764-2016-05-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
- Acronym: TAO
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Otamixaban
- Intervention (Drug): Placebo (for Otamixaban)
- Intervention (Drug): UFH
- Intervention (Drug): Placebo (for UFH)
- Intervention (Drug): Eptifibatide
- Intervention (Drug): Placebo (for Eptifibatide)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial (`cardio:pubmed-23995608`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial (`cardio:pubmed-29895599`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial (`cardio:pubmed-33430604`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a6dad61f669819a95598bdc2047331ae9887950b3f5ac43beb4238893971a315
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
